Equities

Senzime AB (publ)

Senzime AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)6.18
  • Today's Change0.08 / 1.31%
  • Shares traded411.29k
  • 1 Year change-8.04%
  • Beta0.5513
Data delayed at least 15 minutes, as of Nov 13 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.

  • Revenue in SEK (TTM)55.29m
  • Net income in SEK-131.46m
  • Incorporated1999
  • Employees52.00
  • Location
    Senzime AB (publ)Ulls Vag 41UPPSALA 756 51SwedenSWE
  • Phone+46 18515640
  • Fax+46 18515630
  • Websitehttps://senzime.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Acarix AB6.26m-70.95m352.10m9.00--4.75--56.27-0.1168-0.11680.00950.06970.08940.11722.47---101.38-66.93-123.43-77.1288.2779.42-1,133.87-1,483.685.21-328.980.00--7.2043.55-1.11------
ContextVision AB129.64m21.72m371.59m41.0017.113.8912.362.870.28520.28521.701.251.132.364.823,292,377.0018.8929.3923.7943.2796.8398.5816.7627.154.57--0.017--12.197.78-1.77---35.88--
BrainCool AB (publ)37.48m-57.58m376.03m20.00--2.44--10.03-0.2635-0.26350.16950.60710.23782.013.761,561,500.00-36.54-47.14-39.83-70.16-32.65-149.77-153.65-391.453.64-5.860.00--32.0678.35-34.34---11.63--
Nexstim Oyj91.69m-9.65m421.40m39.00--19.49--4.60-0.1223-0.12231.190.27610.81960.22235.28214,040.30-8.62-26.77-14.02-43.9097.2492.11-10.52-38.381.24-5.510.7716---23.9422.08-201.58--19.51--
Integrum AB102.18m-2.52m433.28m36.00--2.41571.674.24-0.1244-0.12445.299.580.57060.56663.592,620,068.00-1.41-1.71-1.55-1.9887.2583.87-2.47-2.875.54-0.66360.0325--40.1935.91124.92--127.10--
Modulight Oyj39.93m-137.20m448.98m79.00--0.7463--11.24-0.2844-0.28440.08361.220.0516-0.31111.9449,271.43-17.72-8.39-18.97-9.10123.49114.69-343.58-56.814.50--0.0965---12.48-8.20-38.69--63.60--
Bioretec Oy47.19m-40.87m449.70m43.00--6.01--9.53-0.1752-0.17520.20240.3180.41041.233.75110,166.80-35.54-66.83-40.92-97.1969.9770.97-86.61-133.494.04--0.0696--32.7819.77-54.02------
SyntheticMR AB (publ)81.53m4.72m496.09m43.00104.944.3843.726.080.11340.11341.962.720.6049--1.532,203,514.003.507.194.248.8570.2769.705.799.08--18.000.006621.5030.6713.0570.34-7.3327.30--
Omda AS414.50m-25.60m592.65m271.00--9.5121.161.43-1.27-1.2720.923.030.584737.9313.471,447,038.00-3.83-4.92-7.72-6.3793.0790.22-6.55-9.831.150.06810.8875--12.3019.83179.30---3.93--
Mentice AB274.55m-23.28m641.78m130.00--4.63205.962.34-0.9104-0.910410.715.420.92432.774.382,250,394.00-7.84-7.69-15.21-13.0785.8983.67-8.48-10.000.9251--0.0285--25.5411.7490.81---10.83--
Gentian Diagnostics ASA144.63m2.19m661.90m58.00345.404.1659.274.580.12620.12629.3510.470.77921.698.402,533,190.001.18-10.761.33-11.8651.6941.461.51-26.995.01--0.0394--32.9827.6354.92---4.92--
Senzime AB (publ)55.29m-131.46m691.35m52.00--2.56--12.50-1.09-1.090.45952.380.15331.574.91---36.44-35.69-39.12-38.0033.27-20.59-237.75-558.682.62--0.0739--154.7761.90-1.09---3.69--
OssDsign AB123.46m-113.80m703.14m27.00--3.13--5.70-1.40-1.401.432.300.43112.506.802,572,083.00-39.74-37.92-43.39-43.5683.9468.10-92.18-203.065.92-21.650.0114--96.8453.26-31.30---56.16--
ADDvise Group AB (publ)1.63bn114.40m768.33m643.0020.223.053.650.47240.59350.59358.383.930.5658.375.772,606,250.003.983.724.824.7742.0748.957.045.891.402.350.69690.940544.3038.6227.62--30.35--
C Rad AB497.02m53.43m941.06m94.0018.073.1915.041.891.581.5814.728.961.235.042.725,712,816.0013.255.0919.167.0246.3043.1210.814.862.32--0.00490.0040.9217.44375.0510.8933.69--
Data as of Nov 13 2024. Currency figures normalised to Senzime AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

31.09%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 20237.57m7.53%
Handelsbanken Fonder ABas of 21 Oct 20245.95m5.92%
Teknik Innovation Norden Fonder ABas of 31 Dec 20234.86m4.84%
Swedbank Robur Fonder ABas of 30 Sep 20244.78m4.75%
Carnegie Fonder ABas of 30 Sep 20244.71m4.69%
FCG Fonder ABas of 30 Sep 20242.02m2.01%
Amundi Asset Management SA (Investment Management)as of 30 Aug 2024952.32k0.95%
SEB Investment Management ABas of 30 Sep 2024256.04k0.26%
Storebrand Asset Management ASas of 30 Sep 2024163.60k0.16%
Alfa Kraft Fonder ABas of 31 Dec 20220.000.00%
More ▼
Data from 31 Dec 2022 - 06 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.